Q2 EARNINGS: Lombard's first US quarter 'encouraging', Mindray slashes sales guidance
This article was originally published in Clinica
Executive Summary
Lombard Medical Technologies was “a bit light on results” during its first quarter as a US-listed company, noted Jefferies analyst Raj Denhoy. But more positively, “there were very encouraging signs for the commercial ramp of [its flagship product] Aorfix,” the analyst added. Aorfix is indicated for the endovascular treatment of abdominal aortic aneurysms (AAA). It got the go-ahead in the US in February 2013, and is currently the only product approved for use in patients with high-angle aneurysms of up to 90 degrees (who account for 30% of the EVAR market).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.